- Home
- OKYO vs MCRB Comparison
OKYO vs MCRB Comparison
Compare OKYO & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OKYO | MCRB |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.4M | 85.7M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | OKYO | MCRB |
|---|---|---|
| Price | $1.59 | $7.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $6.33 | ★ $14.00 |
| AVG Volume (30 Days) | 43.0K | ★ 46.0K |
| Earning Date | 07-18-2025 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.44 | $6.56 |
| 52 Week High | $3.35 | $29.98 |
Technical Indicators
Market Signals| Indicator | OKYO | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 47.69 | 39.65 |
| Support Level | $1.58 | $6.56 |
| Resistance Level | $1.73 | $9.53 |
| Average True Range (ATR) | 0.07 | 0.51 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 32.86 | 44.51 |
Price Performance
Historical ComparisonAbout OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.